Related Experiment Video
Updated: May 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
CROI 2026: Antiretroviral THerapy in Adult, Maternal, and Pediatric Populations With HIV
Shauna H Gunaratne1, Timothy J Wilkin2, Hong-Van Tieu3
1Columbia University Irving Mecial Center, New York, NY, USA.
Abstract:
The 2026 Conference on Retroviruses and Opportunistic Infections provided data on several investigational antiretroviral compounds with the potential for twice-yearly dosing. A complete yearly regimen seems likely to be available in the coming years. Data on doravirine/islatravir showed that this regimen is an effective 2-drug regimen in those initiating antiretroviral therapy (ART) and in those switching from a suppressive regimen. Several abstracts on ART resistance were presented, focusing on the emergence of resistance to integrase strand transfer inhibitors and to lenacapavir. Recent data highlighted new strategies for the empiric treatment of severe pneumonia in infants with HIV, the potential for long-term ART-free remission using broadly neutralizing antibodies and very early initiation of ART, the evaluation of simplified and long-acting ART regimens, and optimizing transition services for adolescents with perinatally acquired HIV to adult care.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Retroviruses
Pharmacokinetics in Pediatric Patients: Drug Excretion
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Treatment Resistent Cancers

